EGFR and adenocarcinoma: A bronchoscopy with rebiopsy was practiced on 08/16/2023 and histopathological report and IHC tests from 08/2023 reconfirmed poorly differentiated adenocarcinoma, ALK-negative EGFR-negative and PD-L1 low expression (TPS = 5%).